Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell
disease characterized by complement-mediated intravascular hemolysis, thrombosis, and …

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell
disease which causes defects in complement inhibiting proteins. The disease presents …

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, hematologic
disorder characterized by uncontrolled terminal complement activation, intravascular …

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal, rare, complement-mediated
hemolytic anemia. PNH can be associated with marrow failure and thrombophilia. We …

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hemolytic and thrombotic condition.
Patients can experience severe anemia due to intravascular hemolysis, thrombotic events …

Eculizumab is indicated for the therapy of patients with symptomatic paroxysmal nocturnal
hemoglobinuria (PNH). Due to inhibition of terminal complement cascade, patients on …

Background: Intravenous (IV) complement component 5 (C5) inhibitors, eculizumab and
ravulizumab, are the current standards of care in patients with paroxysmal nocturnal …

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare, acquired clonal abnormality,
which renders hematopoietic cells exquisitely sensitive to complement-mediated …

The understanding of the clinical manifestations in paroxysmal nocturnal haemoglobinuria
(PNH) has made great progress. The main symptoms of this disease such as abdominal …

Complement C5 inhibitor eculizumab has a great impact on the treatment of patients with
paroxysmal nocturnal hemoglobinuria (PNH). However, this treatment success has a major …